YALE UNIVERSITY Patent applications |
Patent application number | Title | Published |
20160139149 | CHI3L1 FOR THE DETECTION AND TREATMENT OF NONALCOHOLIC STEATOHEPATITIS - Disclosed herein are compositions and methods for detecting nonalcoholic steatohepatitis (NASH) measuring CHI3L1 levels. In some embodiments, the methods described herein can distinguish NASH from nonalcoholic fatty liver disease. CHI3L1 levels can also be used to monitor treatment progress in patients having NASH. Also disclosed herein are compositions and methods for treating NASH by targeting CHI3L1. | 05-19-2016 |
20160089380 | PROGESTERONE IMPREGNATED VAGINAL RING/PESSARY - A progesterone impregnated vaginal ring/pessary includes a circumferential outer ring composed of a progesterone impregnated biomaterial, wherein the outer ring has a substantially circular configuration while lying flat with an outer diameter of 60 mm to 70 mm and a thickness of approximately 5 mm. The vaginal ring/pessary also includes a transparent membrane extending along an interior space defined by the outer ring. The transparent membrane is composed of a silicone polymer, has a thickness of 1 mm to 3 mm, and includes a plurality of apertures, which are 4 mm to 5 mm in diameter, circumferentially spaced about a perimeter of the transparent membrane. | 03-31-2016 |
20160050117 | MANAGING NETWORK FORWARDING CONFIGURATIONS USING ALGORITHMIC POLICIES - Techniques for managing forwarding configurations in a data communications network include accessing, at least one controller, a packet-processing policy defined by a user in a general-purpose programming language other than a programming language of data forwarding element forwarding rules, the packet-processing policy specifying how data packets are to be processed through the data communications network via the at least one controller. A forwarding configuration for at least one data forwarding element in the data communications network may be derived from the user-defined packet-processing policy, and may be applied to the at least one data forwarding element. | 02-18-2016 |
20160044255 | TECHNIQUES FOR PROCESSING IMAGING DATA HAVING SENSOR-DEPENDENT NOISE - Techniques for processing imaging data contaminated by sensor-dependent noise. An imaging method is described. In the imaging method, imaging data corresponding to an imaged region and acquired by at least first and second sensor elements is obtained. A parameterized model is fitted to the imaging data. The parameterized model includes a first sensor-dependent model of noise generated by the first sensor element in a first portion of the imaging data acquired by the first sensor element, and a second sensor-dependent model of noise generated by a second sensor element in a second portion of the imaging data acquired by the second sensor element. The first sensor-dependent noise model differs, at least in part, from the second sensor-dependent noise model. | 02-11-2016 |
20160042649 | SYSTEMS AND METHODS FOR MONITORING, EVALUATION, AND TREATMENT - A computer-implemented method, a computer program product, and a system are provided. A plurality of multi-level cognitive exercises are provided to an individual. Each of the multi-level cognitive exercises includes at least one task to perform. The individual is requested to respond to a cognitive exercise in the plurality of cognitive exercises by performing the at least one task contained in the cognitive exercise. A response provided by the individual to the cognitive exercise is monitored. Based on the monitoring, a determination is made whether the individual performed the at least one task at a predetermined performance level, wherein the performance level is defined by the at least one task contained in the cognitive exercise. Based on the determining, the individual is requested to perform at least another task. At least one activity for the individual to perform is generated. The at least one activity is based on responses to the multi-level cognitive exercises by the individual. | 02-11-2016 |
20160039881 | SITE-SELECTIVE FUNCTIONALIZATION OF GLYCOPEPTIDE ANTIBIOTICS - Site-selective functionalized glycopeptide antibiotics, methods of making and using are described herein. The compounds exhibit improved activity against methicillin-susceptible | 02-11-2016 |
20160032360 | A METHOD FOR A SINGLE CELL ANALYSIS OF TELOMERE LENGTH - The invention relates to a method for single cell analysis of relative telomere length using multiplex pre-PCR followed by a qPCR (SCT-pqPCR). | 02-04-2016 |
20160027636 | LARGE-AREA, LATERALLY-GROWN EPITAXIAL SEMICONDUCTOR LAYERS - Structures and methods for confined lateral-guided growth of a large-area semiconductor layer on an insulating layer are described. The semiconductor layer may be formed by heteroepitaxial growth from a selective growth area in a vertically-confined, lateral-growth guiding structure. Lateral-growth guiding structures may be formed in arrays over a region of a substrate, so as to cover a majority of the substrate region with laterally-grown epitaxial semiconductor tiles. Quality regions of low-defect, stress-free GaN may be grown on silicon. | 01-28-2016 |
20160018402 | IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES - The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer. | 01-21-2016 |
20160017515 | HETEROGENEOUS MATERIAL INTEGRATION THROUGH GUIDED LATERAL GROWTH - Methods are provided for generating a crystalline material. The methods comprise depositing a textured thin film in a growth seed area, wherein the textured thin film has a preferential crystallographic axis; providing a growth channel extending from the growth seed area, the growth channel permitting guided lateral growth; and growing a crystalline material in the growth channel along a direction that is substantially perpendicular to the preferential crystallographic axis of the textured thin film. A preferred crystalline material is gallium nitride, and preferred textured thin films are aluminum nitride and titanium nitride. | 01-21-2016 |
20150372217 | METHODS FOR MAKING A SUPERCONDUCTING DEVICE WITH AT LEAST ONE ENCLOSURE - Some embodiments are directed to a device including multiple substrates comprising one or more troughs. The substrates are disposed such that the one or more troughs form at least one enclosure. At least one superconducting layer covers at least portion of the at least one enclosure. Other embodiments are directed to a method for manufacturing a superconducting device. The method includes acts of forming at least one trough in at least a first substrate; covering at least a portion of the first substrate with a superconducting material; covering at least a portion of a second substrate with the superconducting material; and bonding the first substrate and the second substrate to form at least one enclosure comprising the at least one trough and the superconducting material. | 12-24-2015 |
20150359808 | COMPOSITIONS AND METHODS FOR REDUCING HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. | 12-17-2015 |
20150357550 | SUPERCONDUCTING DEVICE WITH AT LEAST ONE ENCLOSURE - Some embodiments are directed to a device including multiple substrates comprising one or more troughs. The substrates are disposed such that the one or more troughs form at least one enclosure. At least one superconducting layer covers at least a portion of the at least one enclosure. Other embodiments are directed to a method for manufacturing a superconducting device. The method includes acts of forming at least one trough in at least a first substrate; covering at least a portion of the first substrate with a superconducting material; covering at least a portion of a second substrate with the superconducting material; and bonding the first substrate and the second substrate to form at least one enclosure comprising the at least one trough and the superconducting material. | 12-10-2015 |
20150313643 | Dynamic Spine Stablizer - A dynamic spine stabilizer moves under the control of spinal motion providing increased mechanical support within a central zone corresponding substantially to the neutral zone of the injured spine. The dynamic spine stabilizer includes a support assembly and a resistance assembly associated with the support assembly. The resistance assembly generates greater increase in mechanical force during movement within the central zone and lesser increase in mechanical force during movement beyond the central zone. A method for using the stabilizer is also disclosed. | 11-05-2015 |
20150305706 | ESTIMATION OF A MECHANICAL PROPERTY OF ANATOMY FROM MEDICAL SCAN DATA - A mechanical property of anatomy is estimated from a patient in vivo, such as estimating a patient-specific material property of a valve. A morphological model is used to determine anatomy dynamics. A biomechanical model, using the anatomy dynamics, predicts the dynamics, based, at least in part, on one or more material properties. Using an inverse solution based on comparison of dynamics predicted by the biomechanical model and the dynamics determined from the morphological model, values for the material properties are determined. | 10-29-2015 |
20150303655 | METHOD FOR A GAN VERTICAL MICROCAVITY SURFACE EMITTING LASER (VCSEL) - Methods and structures for forming vertical-cavity light-emitting devices are described. An n-side or bottom-side layer may be laterally etched to form a porous semiconductor region and converted to a porous oxide. The porous oxide can provide a current-blocking and guiding layer that aids in directing bias current through an active area of the light-emitting device. Distributed Bragg reflectors may be fabricated on both sides of the active region to form a vertical-cavity surface-emitting laser. The light-emitting devices may be formed from III-nitride materials. | 10-22-2015 |
20150293115 | METHODS AND COMPOSITIONS FOR DETECTING MISFOLDED PROTEINS - Various aspects and embodiments of the present disclosure are directed to methods and compositions (e.g., kits) for the identification of subjects with misfolded proteins in their urine. For example, methods and compositions for determining that a urine sample from a pregnant woman contains or does not contain misfolded are provided. In some embodiments, the presence of misfolded proteins in a urine sample from a pregnant woman is an indication of preeclampsia. | 10-15-2015 |
20150289452 | Modular Living Green Wall System to Provide Heat Rejection - Modular living green wall systems are provided that supply water-cooled heat rejection for building cooling, power generation, industrial, chemical, and other processes that rely on heat rejection to the ambient environment for their efficient operation. Warm water from the process requiring heat rejection is circulated vertically through channels of porous media of the system and is cooled by evaporative and/or convective heat transfer to the ambient air that flows over and/or through the porous media across or counter to the water flow direction. Cool water leaving the system is piped to a heat exchanger of the process to provide the requisite cooling and is returned warm to the modular green wall system to complete the circulation loop. Modular living green wall systems may be assembled using plant modules and water treatment modules that are nested together to form continuous porous vertical water flow channels and a water recirculation system. The plant modules may consist of an inner porous media layer and an exposed porous substrate layer attached to each other and a stackable module housing. The water treatment module may be housed in a compatible stackable housing containing horizontal layers of filtration media. These modules are stacked in an interlocking manner and may be attached to an existing building support structure or alternatively be used to form a free standing living green wall. | 10-15-2015 |
20150282841 | Method For Stabilizing A Spine - Spine stabilization devices, systems and methods are provided in which a single resilient member or spring is disposed on an elongate element that spans two attachment members attached to different spinal vertebrae. The elongate element passes through at least one of the two attachment members, permitting relative motion therebetween, and terminates in a stop or abutment. A second resilient member is disposed on the elongate element on an opposite side of the sliding attachment member, e.g., in an overhanging orientation. The two resilient members are capable of applying mutually opposing urging forces, and a compressive preload can be applied to one or both of the resilient members. | 10-08-2015 |
20150274738 | HYDROPHOBICALLY TAGGED SMALL MOLECULES AS INDUCERS OF PROTEIN DEGRADATION - Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L | 10-01-2015 |
20150272939 | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase - The present invention includes a novel high-throughput screen capable of identifying compounds that inhibit JARID1B demethylase activity or JARID1A demethylase activity. The present invention further includes novel inhibitors of JARID1B demethylase activity and/or JARID1A demethylase activity, and methods using the same. | 10-01-2015 |
20150258092 | RIBOSOME STRUCTURE AND PROTEIN SYNTHESIS INHIBITORS - The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism. | 09-17-2015 |
20150241481 | WIRELESS JOSEPHSON BIFURCATION AMPLIFIER - A wireless Josephson-junction-based amplifier is described that provides improved tunability and increased control over both a quality factor Q and participation ratio p of the amplifier. The device may be fabricated on a chip and mounted in a waveguide. No wire bonding between the amplifier and coaxial cables or a printed circuit board is needed. At least one antenna on the chip may be used to couple energy between the waveguide and wireless JBA. The amplifier is capable of gains greater than 25 dB. | 08-27-2015 |
20150233929 | IDENTIFICATION OF CANCER PROTEIN BIOMARKERS USING PROTEOMIC TECHNIQUES - The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer. | 08-20-2015 |
20150218644 | THERAPY WITH CLOSTRIDIUM PERFRINGENS ENTEROTOXIN TO TREAT OVARIAN AND UTERINE CANCER - The invention discloses high levels of receptors for | 08-06-2015 |
20150204864 | SYSTEM, DEVICE AND METHOD FOR HIGH-THROUGHPUT MULTI-PLEXED DETECTION - The present invention relates to a system, device, and method for the high throughput multiplexed detection of a wide number of compounds. The invention comprises of a microwell array coupled to a capture agent array to form a plurality of interfaces between a microwell and a set of immobilized capture agents. The set of capture agents comprises a plurality of distinguishable features, with each feature corresponding to the detection of a particular compound of interest. In certain embodiments, each microwell is configured to contain a single cell. The invention is therefore capable of performing a high throughput analysis of single cell profiles, including profiles of secreted compounds. | 07-23-2015 |
20150182172 | Systems and Methods Utilizing Plethysmographic Data for Distinguishing Arterial and Venous Oxygen Saturations - Apparatus, systems and methods are provided for using the PG waveform to determine peripheral venous and arterial saturations. Generally, saturations are determined by isolating an indicator of venous or arterial blood volume in each of a plurality of PG waveforms and using the isolated indicators to determine saturation in the corresponding region of the vasculature. Indicators may include respiratory induced variations of AC and/or DC components of the PG waveforms, peaks of the PG waveforms, troughs of the PG waveforms, venous pulsations of the PG waveforms, etc. Indicators may further be isolated in either the time or frequency domain. The isolated indicators may advantageously be normalized, e.g., based on a baseline of the PG waveform or a derivative thereof. | 07-02-2015 |
20150158067 | METHOD AND SYSTEM BASED ON THERMOPLASTIC FORMING TO FABRICATE HIGH SURFACE QUALITY METALLIC GLASS ARTICLES - A method of processing BMGs in a non-ideal environment (such as air) to create a uniform and smooth surface is provided. By utilizing the contact-line movement and an engineered flow pattern during TPF the method is able to create complex BMG parts that exhibit uniform smooth appearance or even can be atomically smooth. In addition, to mending surface imperfections, this method also eliminates void formation inside the material, allows for the creation of precise patterns of homogeneous appearance, and forms improved mechanical locks between different materials and a BMG. | 06-11-2015 |
20150157988 | SPIRAL WOUND MEMBRANE MODULE FOR FORWARD OSMOTIC USE - A spiral wound membrane module for forward osmotic use is disclosed. The membrane module may generally include a forward osmosis membrane in a spiral wound configuration. The module may include two inlets and two outlets, and may define first and second fluid flow paths. The inlets to each of the fluid flow paths may be generally isolated so as to prevent mixing. In some embodiments, the membrane module may include a distributer region and a collector region. | 06-11-2015 |
20150152500 | DIAGNOSIS AND TREATMENT OF AGE RELATED MACULAR DEGENERATION - Methods, compositions and kits for diagnosis and treatment of age related macular degeneration. | 06-04-2015 |
20150118318 | Methods of Treating Inflammatory and Autoimmune Diseases and Disorders - Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder. The nanolipogel includes a lipid bilayer surrounding a hydrogel core, which may optionally include a host molecule, for example, an absorbent such as a cyclodextrin or ion-exchange resin. In preferred embodiments at least one of active agents is an immunosuppressant. | 04-30-2015 |
20150110742 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) and Toll-like receptor agonist (TLR) through a linker and a multifunctional connector group or molecule. | 04-23-2015 |
20150105361 | METHODS FOR TREATING POLYCYSTIC KIDNEY DISEASE AND POLYCYSTIC LIVER DISEASE - The present invention provides compounds of Formula (I) or (II), which are thought to be able to inhibit mTOR (mammalian target of rapamycin) signaling pathway, induce UPR (unfolded protein response), and/or perturb mitochondrial function of a cyst cell (e.g., a cyst cell causing polycystic kidney disease (PKD, e.g., autosomal dominant PKD (ADPKD) or autosomal recessive PKD (ARPKD)) or polycystic liver disease (PLD, e.g., autosomal dominant PLD (ADPLD) or autosomal recessive PLD (ARPLD)). The invention also provides pharmaceutical compositions, kits, and methods involving the compounds described herein for use in treating PKD or PLD, inhibiting the growth of a cyst cell, and/or killing a cyst cell. | 04-16-2015 |
20150086617 | Liposome Structures And Methods of Use Thereof - The present application relates to compositions comprising and methods of using a liposome comprising a pHLIP polypeptide, wherein a lipid bilayer of the liposome is substantially free of the pHLIP polypeptide. | 03-26-2015 |
20150045611 | Suspension/Retraction Device for Surgical Manipulation - A device that can be delivered into a body cavity to manipulate tissue intracorporeally while being controlled extracorporeally and a method of using the device to perform a single-port laparoscopic or natural orifice surgery are provided. The device is capable of being passed through an interior diameter of a single port into the body cavity. The device may include an anchor or suspension element that is attachable or mountable to the tissue intracorporeally, a guide element attached to the anchor or suspension element that allows for manipulation of at least one structure in at least one direction, and at least one structure attached to a suture or thread that is passable through the interior diameter of the port and positionable by the guide element. The structure is controllable extracorporeally by manipulating the suture or thread so that the structure moves in at least one direction intracorporeally. | 02-12-2015 |
20150044239 | Compositions and Methods for Diagnosing, Preventing and Treating Intracranial Aneurysms - The present invention relates to compositions and methods for diagnosing, preventing and treating intracranial aneurysm. | 02-12-2015 |
20150030701 | ANTIMICROBIAL COMPOSITIONS AND METHODS - Disclosed are compositions and methods for antimicrobial use. The compositions contain a small antimicrobial agent and a permeabilizing agent. The antimicrobial compositions can be antifungal or antibacterial compositions. | 01-29-2015 |
20150025230 | Single Nucleotide Polymorphisms in BRCA1 and Cancer Risk - The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (SNPs), within breast and ovarian cancer associated genes that modify the binding efficacy of microRNAs (miRNAs). In a preferred embodiment, methods of the invention identify a SNP that decreases expression of the BRCA1 gene by increasing or decreasing the binding efficacy of at least one miRNA. Alteration of miRNA binding to BRCA1 by the introduction of SNPs within miRNA binding sites modulates or decreases BRCA1 expression, ultimately leading to the unregulated cell proliferation of a breast or ovarian cancer cells. | 01-22-2015 |
20150023873 | EVALUATION OF PRESENCE OF AND VULNERABILITY TO ATRIAL FIBRILLATION AND OTHER INDICATIONS USING MATRIX METALLOPROTEINASE-BASED IMAGING - The invention provides, in some embodiments, methods relating to assessing increased risk of developing atrial fibrillation (AF), and/or the likelihood of responding to particular AF therapies using imaging agents comprising an MMP inhibitor linked to an imaging moiety. The invention further provides methods for evaluating the presence of the risk of developing other cardiovascular conditions and assessing the effectiveness of treatment or other intervention for such conditions by determining MMP levels. | 01-22-2015 |
20140377278 | Compositions and Methods for Assessing and Treating Inflammatory Diseases and Disorders - The present invention relates to the discovery that the disruption of inflammasome function leads to an altered microbiota that affects the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and determining the relative proportions of the constituents of a subject's microbiota, methods of modifying an altered microbiota population in a subject, and compositions and methods for treating inflammatory diseases and disorders in a subject in need thereof. | 12-25-2014 |
20140371712 | CONVECTION ENHANCED DELIVERY APPARATUS, METHOD, AND APPLICATION - An embodiment of the invention is directed to a microfabricated, silicon-based, Convection Enhanced Delivery (CED) device. The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening. The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e.g., a drug) to the microfabricated device. The device may have multiple channels disposed side by side or in different surfaces of the device. The device may be rigid, or flexible, in which case a flexible device can be attached to a bio-degradable support scaffold that provides sufficient structural rigidity for insertion of the device into the target tissue. In certain “functionalized” embodiments of the invention, the CED device is equipped with integrated electrodes and/or a sensor (e.g., glutamate) to detect and convey selective parametric information. Another embodiment of the invention is directed to a CED method for drugs and/or other agents. The method may comprise the delivery of enzymes or other materials to modify tissue permeability and improve drug diffusion. Another embodiment of the invention is directed to a method for making a device for CED of drugs. | 12-18-2014 |
20140371233 | COMPOSITIONS AND METHODS FOR TREATING A -MODULATED DISEASE OR DISORDER OR IMPROVING COGNITION IN A SUBJECT - The present invention provides compositions and methods for treating and preventing an Aβ-modulated disease. In certain embodiments, the invention provides an inhibitor of Fyn tyrosine kinase, and methods of using the same. In certain embodiments, the inhibitor of the invention inhibits Aβ oligomer induced signaling and reduces or halts the progression of Alzheimer's Disease. | 12-18-2014 |
20140369586 | SYSTEMS AND METHODS FOR AUTOMATED ANALYSIS OF CELLS AND TISSUES - Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed. | 12-18-2014 |
20140348889 | Compositions and Methods for Treating and Preventing Neointimal Stenosis - Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed. | 11-27-2014 |
20140336444 | System and Method for Heart Pump Interrogation and Inspection - The present invention relates to systems and methods for in situ inspection, interrogation, and maintenance of heart pump function in subjects with an implanted heart pump. In certain embodiments, the system comprises a catheter assembly deliverable to the inflow port and outflow port of the implanted heart pump. The system comprises additional components used to examine pump function and prevent malfunction. In certain embodiments, the invention allows for temporary, mid-term, or permanent exclusion of the implanted heart pump from cardiac function without surgically removing the pump. | 11-13-2014 |
20140319044 | NANOPARTICLE-FUNCTIONALIZED MEMBRANES, METHODS OF MAKING SAME, AND USES OF SAME - Nanoparticle functionalized membranes, where the surface of the membranes is nanoparticle functionalized. The nanoparticles closest to the membrane surface are covalently bonded to the membrane surface. For example, the membranes are forward osmosis, reverse osmosis, or ultrafiltration membranes. The membranes can be used in devices or water purification methods. | 10-30-2014 |
20140302523 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same - The present invention includes compounds that are useful in perturbing or disrupting the function of a transmembrane or intracellular protein, whereby binding of a compound to the transmembrane or intracellular protein induces proteasomal degradation of the transmembrane or intracellular protein. The present invention further includes a method of inducing proteasomal degradation of a transmembrane or intracellular protein. The present invention further includes a method of identifying or validating a protein of interest as a therapeutic target for treatment of a disease state or condition. | 10-09-2014 |
20140299751 | Superconducting Single Photon Detector - The present invention provides a device and system for high-efficiency and low-noise detection of single photons within the visible and infrared spectrum. In certain embodiments, the device of the invention can be integrated within photonic circuits to provide on-chip photon detection. The device comprises a traveling wave design comprising a waveguide layer and a superconducting nanowire atop of the waveguide. | 10-09-2014 |
20140296154 | METHOD OF PREVENTING DEVELOPMENT OF PSORIATIC LESIONS - The present invention relates to a method of inhibiting onset of or preventing development of a psoriatic lesion in a patient having psoriasis. The method comprises administering to a patient having psoriasis an effective amount of an agent that inhibits NF-κB activity under conditions effective to inhibit onset of or prevent development of psoriatic lesions. Another aspect of the invention relates to a method of treating an early stage psoriatic lesion on a patient by contacting the early stage psoriatic lesion of a patient with an effective amount of an agent that inhibits NF-κB activity, whereby said contacting inhibits development of the early stage psoriatic lesion. Both transgenic and nontransgenic approaches are contemplated. | 10-02-2014 |
20140276304 | Friction-Based Orthotic Impedence Modulation Device - The present invention relates to an impedance modulation device for an orthotic application. The device includes a high-stiffness loading spring, a low-stiffness return spring, a shaft having an output connector, and an engagement mechanism. When the engagement mechanism engages the shaft, the device exhibits a high stiffness at the output connector, and wherein when the engagement mechanism disengages the shaft, the device exhibits a low stiffness at the output connector. | 09-18-2014 |
20140275727 | Implantable Heart Pump Controller - The present invention provides devices, systems, and methods for control of ventricular assist devices. The invention includes an implantable controller that is operatively programmed to direct physiological flow through a ventricular assist device that is substantially synchronized to the cardiac cycle of the subject. The implantable controller is also communicatively connected to an external control unit, such that the implantable controller can transmit data to the external control unit, and instructions can be sent from the external control unit to the implantable controller. | 09-18-2014 |
20140256574 | Compositions and Methods for Diagnosing Diseases and Disorders Associated with Beta Cell Death - The present invention relates to compositions and methods for detecting cell death by detecting cell DNA in a biological sample. The invention relates the discovery that the presence of hypomethylated β cell DNA outside of the pancreas of a subject is indicative of β cell death. Thus, in one embodiment, the invention is a method of detecting hypomethylated β cell insulin DNA in a biological sample of a subject including the steps of: obtaining a biological sample from the subject, where the biological sample is obtained from outside of the subject's pancreas and where the biological sample contains β cell insulin DNA; determining the methylation status of at least one of the CpG dinucleotides in the β cell insulin DNA, where when at least one of the CpG dinucleotides in the β cell insulin DNA is determined to be unmethylated, the hypomethylated β cell insulin DNA is detected. | 09-11-2014 |
20140249212 | Compositions and Methods for Transient Expression of Recombinant RNA - Compositions for transient but prolonged exogenous mRNA expression through the use of the transcription system of negative strand RNA viruses, and methods of use thereof are disclosed. In some embodiments, the system contains only RNAs and does not include any DNA molecules. The compositions typically include an RNA template unit (rTeUn) that includes a virus regulatory sequences operably linked to a coding sequence of interest. The rTeUn is typically transfected to a host cell's cytoplasm in the presence of virus expression system proteins that mediate replication of the rTeUn and transcription of the transgene. The rTeUn RNA bonded to viral proteins exhibits high resistance to degradation, prolonged duration of expression, and is free of viral genes. The compositions can be used to reprogram cell. For example, the compositions and methods can be used to redirected lymphocytes to target cancer cells, or to dedifferentiate somatic cells into induce pluripotent stem cells. | 09-04-2014 |
20140238917 | OSMOTIC DESALINATION PROCESS - An energy efficient desalination process that does not produce waste products involves the extraction of water from a first solution, such as seawater, by using a second concentrated solution to draw the water from the first solution across a semi-permeable membrane. By manipulating the equilibrium of the soluble and insoluble species of solute within the second solution in favor of the soluble species of the solute, a saturated second solution can be used to generate osmotic pressure on the first solution. Also, by adjusting the equilibrium in favor of the less soluble species after the water has been drawn from the first solution, a portion of the solute can easily be precipitated out. Heating the second solution decomposes the solute into its constituent gases. The constituent gases and precipitated solute may be recycled through the process to affect the changes in equilibrium and eliminate waste products. Additionally, by using the waste steam from industrial sources and a heat pump to effectively distribute heat through the present method, the present method exhibits greater energy efficiency than prior art methods. | 08-28-2014 |
20140238574 | DESIGN OF A MOLD FOR FORMING COMPLEX 3D MEMS COMPONENTS - A mold structure having high-precision multi-dimensional components includes: depositing an oxide layer on a top surface of a plurality of semiconductor substrates, patterning a design integrated in one or more of the oxide layers; repositioning the substrates to enable the oxide layers make contact with one another; bonding in sequential order the repositioned substrates using a dielectric bonding, forming a three dimension (3D) mold; filling the 3D mold with filling material and removing the overburden filling material present on a top surface of the component. | 08-28-2014 |
20140235507 | Protein Chips for High Throughput Screening of Protein Activity - The present invention relates to protein chips useful for the large-scale study of protein function where the chip contains densely packed reaction wells. The invention also relates to methods of using protein chips to assay simultaneously the presence, amount, and/or function of proteins present in a protein sample or on one protein chip, or to assay the presence, relative specificity, and binding affinity of each probe in a mixture of probes for each of the proteins on the chip. The invention also relates to methods of using the protein chips for high density and small volume chemical reactions. Also, the invention relates to polymers useful as protein chip substrates and methods of making protein chips. The invention further relates to compounds useful for the derivatization of protein chip substrates. | 08-21-2014 |
20140234269 | Endometrial Derived Stem Cells and Their Methods of Use - The present invention provides a method of making an insulin-producing cell derived from an endometrial stromal stem cell (ESSC). The invention includes the progeny of ESSC, including any cell type generated during the differentiation of ESSC towards cells that produce insulin and exhibit cell markers characteristic of insulin producing cells. The cells of the invention can be used to treat various diseases such as diabetes type I, diabetes type II and gestational diabetes. | 08-21-2014 |
20140217012 | MULTIBLOCK COPOLYMER FILMS, METHODS OF MAKING SAME, AND USES THEREOF - A method for forming an isoporous graded film comprising multiblock copolymers and isoporous graded films. The films have a surface layer and a bulk layer. The surface layer can have at least 1×10 | 08-07-2014 |
20140213485 | Methods For Preparing cDNA From Low Quantities of Cells - Methods for preparing cDNA libraries from single and low quantities of cells are disclosed. The methods are based on the principles of multi-strand displacement amplification or semi-random primed polymerase chain reaction. The methods typically include a step of reverse transcription and subsequent amplification of cDNA. The methods can be adapted for preparation of cDNA libraries that are representative of mRNA or whole RNA expressed by the cell or cells. The cDNA is suitable for sequencing or microarray analysis. | 07-31-2014 |
20140206003 | Genetic Lesion Associated with Cancer - The invention comprises methods for identifying mutations within the 3′UTR of genes that lead to increased risk or probability of developing cancer. | 07-24-2014 |
20140204442 | CONTROLLING ABSORPTION OF LIGHT IN A CAVITY - Described is a method of controlling the absorption of light in a cavity, a system in which absorption is so controlled, and an interferometer embodying the underlying physical concept. Materials can be made to completely absorb incident light when the light is imposed in a specific pattern of illumination. Coherent perfect absorption, as the process is referred to, is achieved when a cavity is illuminated coherently and monochromatically by the time-reverse of the output of a lasing mode. Varying the parameters of the incident light and/or of the cavity allows the absorption of the incident light by the cavity to be controlled; enhanced or even reduced. | 07-24-2014 |
20140200184 | Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury - The present invention provides compositions and methods for the detection, treatment, and prevention of a kidney injury. The invention relates to the discovery that chitinase 3-like 1/Brp-39/YKL-40 serves as both a biomarker for the degree of kidney injury and a critical mediator of a reparative response in the kidney. | 07-17-2014 |
20140191186 | Regenerative Nanosensor Devices - The present invention provides a regenerative nanosensor device for the detection of one or more analytes of interest. In certain embodiments, the device comprises a nanostructure having a reversible functionalized coating comprising a supramolecular assembly. Controllable and selective disruption of the assembly promotes desorption of at least part of the reversible functionalized coating thereby allowing for reuse of the regenerative device. | 07-10-2014 |
20140186648 | Method for Imprinting and Erasing Amorphous Metal Alloys - The present invention relates to materials, methods and apparatuses for performing imprint lithography using amorphous metallic materials. The amorphous metallic materials can be employed as imprint media and thermoplastic forming processes are applied during the pattern transfer procedure to produce micron scale and nanoscale patterns in the amorphous metallic layer. The pattern transfer is in the form of direct mask embossing or through a serial nano-indentation process. A rewriting process is also disclosed, which involves an erasing mechanism that is accomplished by means of a second thermoplastic forming process. The amorphous metallic materials may also be used directly as an embossing mold in imprint lithography to allow high volume imprint nano-manufacturing. This invention also comprises of a method of smoothening surfaces under the action of the surface tension alone. | 07-03-2014 |
20140178392 | Nogo Receptor-Mediated Blockade of Axonal Growth - Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease. | 06-26-2014 |
20140170135 | EGFR EXPRESSION IS ASSOCIATED WITH DECREASED BENEFIT FROM TRASTUZUMAB IN THE NCCTG N9831 TRIAL - The subject invention provides a method for treating a patient having a tumor associated with HER2+ breast cancer comprising: measuring in a sample of the patient's tumor a level of expression of epidermal growth factor receptor protein by using an antibody that detects the cytoplasmic domain of epidermal growth factor receptor; and comparing the level of expression of epidermal growth factor receptor protein in the patient's tumor so measured with a reference value; wherein if the level of expression of epidermal growth factor receptor measured is higher than the reference value, treating the patient with a therapy other than trastuzumab. | 06-19-2014 |
20140165566 | Osmotic Heat Engine - A method of converting thermal energy into mechanical work that uses a semi-permeable membrane to convert osmotic pressure into electrical power. A closed cycle pressure-retarded osmosis (PRO) process known as an osmotic heat engine (OHE) uses a concentrated ammonia-carbon dioxide draw solution to create high osmotic pressures which generate water flux through a semi-permeable membrane against a hydraulic pressure gradient. The depressurization of the increased draw solution volume in a turbine produces electrical power. The process is maintained in steady state operation through the separation of the diluted draw solution into a re-concentrated draw solution and deionized water working fluid, both for reuse in the osmotic heat engine. | 06-19-2014 |
20140163299 | Ultraviolet and Hydrogen Peroxide or Ozone or Ozone and Hydrogen Peroxide Treatment to Simultaneously Control Nitrosamine, Nitramine, Amine and Aldehyde Emissions from Amine-Based Carbon Capture - Apparatuses for controlling emissions of carbon capture facilities and associated methods are disclosed that generally involve a chamber defining at least one wash-water packing. The exemplary apparatuses further include at least one washwater return line, a UV treatment zone and a hydrogen peroxide treatment zone. The UV treatment zone generally receives UV energy sufficient to substantially destroy a first emission compound and the hydrogen peroxide treatment zone generally receives a hydrogen peroxide medium sufficient to substantially oxidize a second emission compound to a less volatile final product. An alternative exemplary apparatus generally involves a UV treatment zone and an ozonation treatment zone, further including a hydrogen peroxide treatment zone applied within the ozonation treatment zone. The exemplary methods generally include applying at least one of a UV treatment, a hydrogen peroxide treatment and an ozonation treatment. | 06-12-2014 |
20140155459 | Compositions and Methods of Using Micro RNAs - The present invention provides compositions and methods of using microRNAs to treat pulmonary arterial hypertension. In one aspect, methods are disclosed that are useful for identifying a subject in need of therapeutic intervention to reduce or improve a symptom of pulmonary arterial hypertension, reducing proliferation of pulmonary vascular cells in a subject, or treating pulmonary arterial hypertension in a subject. In another aspect, compositions include an inhibitor of fibroblast growth factor 2 (FGF2) expression comprising at least one of: a mature sequence of miR-424 or miR-503; a pri-miRNA of miR-424 or miR-503; a pre-miRNA of miR-424 or miR-503; and the complement thereof. Pharmaceutical compositions for reducing proliferation of pulmonary vascular cells in a subject in need thereof and biomarker panels are also disclosed. | 06-05-2014 |
20140154744 | Compositions and Methods for Making Selenocysteine Containing Polypeptides - Non-naturally occurring tRNA | 06-05-2014 |
20140148353 | PROTEIN EXPRESSION-BASED CLASSIFIER FOR PREDICTION OF RECURRENCE IN ADENOCARCINOMA - A method for making a prognosis for a patient afflicted with a type of cancer which comprises (a) determining in a sample of a tumor from the patient a level of expression for at least three biomarkers from the following group: thyroid transcription factor-1 (TTF1), signal transducer and activator of transcription-3 (STAT-3), beta-catenin and cyclin D1; (b) calculating a score based on the levels of expression determined in step (a); (c) correlating the score obtained in step (b) with a series of predetermined reference scores associated with a series of prognoses; so as to thereby make a prognosis for the patient. | 05-29-2014 |
20140147484 | Cell-Free Tissue Engineered Vascular Grafts - A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation. | 05-29-2014 |
20140147448 | NOVEL COMPOSITIONS AND METHODS OF PREVENTING OR AMELIORATING ABNORMAL THROMBUS FORMATION AND CARDIOVASCULAR DISEASE - The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased cardiovascular risk. | 05-29-2014 |
20140145073 | Use of cryogenic ion chemistry to add a structural characterization capability to mass spectrometry through linear action spectroscopy - The present invention relates to mass spectrometry and infrared spectrometry and in particular, to a method of providing highly resolved infrared spectra of mass-selected, complex (e.g., biopolymer, polypeptide, organic chemical, an organometallic compound, a carbohydrate, a polynucleotide or oligonucleotide compound) ions to be obtained in a general fashion. | 05-29-2014 |
20140128278 | Calibration of Nanostructure Sensors - The present invention relates to uniform nanostructure biosensors and methods of calibrating the response of nanostructure biosensors. The invention overcomes device to device variability that has made quantitative detection difficult. The described biosensors have uniform characteristics that allow for more reliable comparison across devices. The methods of the invention comprise normalizing the initial current rate, as measured by the nanostructure biosensor following the addition of an analyte, to device characteristics of the biosensor. The device characteristics of the biosensor which can be used to normalize the response include baseline current and transconductance. Calibration of responses allows for the generation of calibration curves for use in all devices to quantitatively detect an analyte, without the need for individual device calibration. | 05-08-2014 |
20140127126 | Compositions and Methods for Assessing and Treating Adrenal Diseases and Disorders - The present invention relates to the discovery that mutations in KCNJ5 are associated with adrenal diseases and disorders. The invention includes compositions and methods for the assessment, characterization and treatment of adrenal diseases and disorders, based upon the presence or absence of a KCNJ5 mutation that is associated with an adrenal disease or disorder. | 05-08-2014 |
20140114977 | SYSTEM AND METHOD FOR DOCUMENT ANALYSIS, PROCESSING AND INFORMATION EXTRACTION - The present invention is directed to a method and computer system for representing a dataset comprising N documents by computing a diffusion geometry of the dataset comprising at least a plurality of diffusion coordinates. The present method and system stores a number of diffusion coordinates, wherein the number is linear in proportion to N. | 04-24-2014 |
20140105870 | Differentiation of Human IPS Cells to Human Alveolar Type II Via Definitive Endoderm - The present invention relates to compositions and methods for generating populations of tissue precursor cells from pluripotent cells, and preferably induction of stem cells into definitive endoderm to generate anterior foregut endoderm from pluripotent cells. The anterior foregut endoderm cells can then be differentiated into an alveolar epithelial type II cell. | 04-17-2014 |
20140066328 | PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs) - Described are embodiments related to gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) biomarkers and agents, systems, and kits for detecting the same, and associated GEP-NEN diagnostic, prognostic, and predictive methods and uses thereof, such as detection, prediction, staging, profiling, classification, and monitoring treatment efficacy and other outcomes. | 03-06-2014 |
20140065615 | The KRAS Variant and Tumor Biology - The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant. | 03-06-2014 |
20140058273 | Apparatus, Systems and Methods Analyzing Pressure and Volume Waveforms in the Vasculature - Apparatus, systems and methods are provided for analyzing relative compliance in the peripheral vasculature that generally involve generating a plethysmograph (PG) signal, generating one or more pressure waveforms and comparing the pressure waveform(s) relative to the PG signal to determine compliance indexes associated particular regions of the vasculature. A relative compliance ratio may also be determined by comparing arterial and venous relative compliance indexes. Apparatus, systems and methods are also provided for analyzing a PG waveform that generally involve generating a plethysmograph (PG) signal and comparing amplitude modulation of the PG signal relative to baseline modulation of the PG signal to estimate a relationship between left ventricular end diastolic pressure and stroke volume. The estimated relationship may account for a phase offset for the time between when changes in venous return affect left ventricular end diastolic pressure and stroke volume. | 02-27-2014 |
20140058239 | FAULT-TOLERANT MULTIELECTRODE ARRAY FOR BRAIN IMPLANTABLE DEVICE - A multielectrode array with fault-tolerance for use in conjunction with a brain implantable device includes a sensor grid composed of a plurality of sensors, the plurality of sensors including primary sensors and spare sensors. The multielectrode array also includes signal processing circuitry associated with the plurality of sensors and a control system associated with the sensor grid for replacing faulty primary sensors with spare sensors. | 02-27-2014 |
20140051076 | IDENTIFICATION OF GENE ASSOCIATED WITH READING DISABILITY AND USES THEREFOR - The present invention relates to identification of a human gene, DCDC2 (MIM: 605755), associated with susceptibility for developing reading disability (RD), which is useful in identifying or aiding in identifying individuals at risk for developing RD, as well as for diagnosing or aiding in the diagnosis of RD. | 02-20-2014 |
20140050723 | Cell-Penetrating Anti-DNA Antibodies and Uses Thereof Inhibit DNA Repair - Antibodies that penetrate cell nuclei and inhibit DNA repair or interfere with DNA metabolism are provided for treatment of cancer (both directly and by sensitizing cancer cells to DNA-damaging treatments) or inhibiting or preventing viral infection, proliferation or metabolism. The method involves treating cells with a composition containing cell-penetrating anti-DNA antibodies or derivatives thereof, alone or in combination with treatment that induces DNA damage such as DNA-damaging chemotherapy or radiation. The impact of the cell-penetrating anti-DNA antibodies or derivatives thereof is potentiated in cancer cells that are deficient in DNA repair, and the cell-penetrating anti-DNA antibodies or derivatives thereof are synthetically lethal to cancer cells with DNA repair deficiencies. | 02-20-2014 |
20140030266 | Compositions and Methods for Diagnosing and Treating Diseases and Disorders Associated With D-DT - The present invention relates to the discovery that altered levels of D-DT (also known as MIF-2) are associated with disorders and diseases. Thus, the present invention relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with an elevated level of D-DT. The present invention also relates to compositions and methods useful of the assessment, diagnosis, characterization, prevention and treatment of disorders and diseases associated with a reduced level of D-DT. | 01-30-2014 |
20140024590 | KRAS-Variant And Endometriosis - The invention provides methods for predicting an increased risk or probability of developing endometriosis in a patient based upon the patient's KRAS variant status. | 01-23-2014 |
20140018306 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. | 01-16-2014 |
20130340105 | Human SIRPAalpha Transgenic Animals and Their Methods of Use - The invention relates generally to compositions and methods of using transgenic non-human animals expressing human SIRPα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human SIRPα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function. | 12-19-2013 |
20130337503 | MUTANT PROTEINASE WITH REDUCED SELF-CLEAVAGE ACTIVITY AND METHOD OF PURIFICATION - The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins. | 12-19-2013 |
20130323710 | Methods for Inducing the Differentiation of Blood Monocytes into Functional Dendritic Cells - Methods are provided for treating blood monocytes to produce functional antigen presenting dendritic cells. An extracorporeal quantity of a subject's blood is treated to separate the blood into a plasma component containing proteins, a platelet component and a buffy coat component. A plastic treatment device is provided having plastic channels that allow transmittance of light to the interior of the plastic device and a light source that produces light of a wave length selected to activate the photoactivatable agent. The plasma component containing proteins is first pumped through the plastic treatment device, followed by the platelet component and finally the buffy coat component. The resulting treated cells may be incubated or reinfused directly to the subject. | 12-05-2013 |
20130322817 | NANOMECHANICAL PHOTONIC DEVICES - Devices which operate on gradient optical forces, in particular, nanoscale mechanical devices which are actuable by gradient optical forces. Such a device comprises a waveguide and a dielectric body, with at least a portion of the waveguide separated from the dielectric body at a distance which permits evanescent coupling of an optical mode within the waveguide to the dielectric body. This results in an optical force which acts on the waveguide and which can be exploited in a variety of devices on a nano scale, including all-optical switches, photonic transistors, tuneable couplers, optical attenuators and tuneable phase shifters. | 12-05-2013 |
20130315934 | Methods and Compositions for Assessing and Treating Cancer - The invention relates to methods and compositions for identifying mutations associated with cancer, such as melanoma. More particularly, the invention relates to methods and compositions for assessing particular mutations as markers for cancer, such as melanoma. Such methods and compositions allow medical providers to diagnose cancer, such as melanoma, based upon the presence of one or more particular mutations in a subject, as compared with an otherwise healthy control. The methods and compositions are also useful in guiding the type of therapy to be applied, and monitoring the effects of the therapy applied. | 11-28-2013 |
20130313113 | Microfluidic Processing of Target Species in Ferrofluids - Disclosed are systems, devices, methods, and other implementations, including a device to detect at least one target species in a sample, with the device including a microfluidic channel configured to receive the sample containing the at least one target species and a biocompatible ferrofluid in which the at least one target species is suspended, a detector to determine the at least one target species in the sample, and at least two of electrodes positioned proximate the microfluidic channel, the at least two electrodes configured to generate controllable magnetic forces in the sample containing the ferrofluid when a controllable at least one electrical current is applied to the at least two electrodes. The generated controllable magnetic forces causes the at least one target species to be directed towards the detector. Also disclosed are devices for separating target species in a ferrofluid, and for focusing target species suspended in a ferrofluid. | 11-28-2013 |
20130309641 | Systems and Methods for Assessing Behavioral Patterns and Promoting Behavioral Change by Comparing Gaming Performance to Aspirational Attributes - Systems and methods are provided for assessing behavioral patterns and promoting behavioral change by comparing the performance of a user within a videogame or simulation to aspirational attributes (e.g., attributes defining an aspirational avatar) selected by the user in advance of the game, and conveying the results of the comparison to the user with video, graphics, text, audio, other media, or a combination thereof. The assessment can include guidance or suggestions regarding the need for behavioral modification and/or an identification of the user's choices that caused the user to attain, or fall short of the user's predefined aspirations. | 11-21-2013 |
20130306262 | Blow Molding of Bulk Metallic Glass - A very low pressure gas or blow forming process for shaping a bulk metallic glass (BMG) in its supercooled liquid state that avoids the frictional stick forces experienced by conventional shaping techniques by engineering the expansion of a pre-shape or parison of BMG material such that substantially all of the lateral strain required to form the final article is accomplished prior to the outer surface of the parison contacting the surface of the shaping apparatus is provided. The capability offered by the inventive shaping process to avoid the frictional forces exerted by the shaping apparatus surface allows for the formation of precision net-shape complex multi-scale parts and components using processing conditions inaccessible by conventional processes. | 11-21-2013 |
20130302409 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY - The present invention generally relates to the field of cancer and methods and compositions for cancer immunotherapy. In one embodiment, a method for treating cancer in a patient comprises the steps of (a) administering at or near the cancer site an effective amount of a composition that promotes a therapeutic immune response to the cancer; and (b) ablating the cancer. In another embodiment, a method for treating an abnormal cellular proliferation in a patient comprises the steps of (a) administering at or near the site of the abnormal cellular proliferation an effective amount of a composition that promotes a therapeutic immune response to the abnormal cellular proliferation comprising (i) a polymeric particle; and (ii) optionally one or more therapeutic agents encapsulated in or incorporated on or into the polymeric particle; and (b) ablating the abnormal cellular proliferation. | 11-14-2013 |
20130274303 | METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION - The present disclosure relates to methods of treating a stimulant addiction of a patient comprising administering to a patient in need a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor thereby decreasing stimulant reward, inducing aversion for the stimulant or preventing relapse in the patient. The disclosure further encompasses methods whereby a therapeutically effective dose of a selective dopamine beta-hydroxylase inhibitor is determined by: characterizing the genetic profile of the patient with respect to the gene encoding dopamine beta-hydroxylase, a polymorphism therein correlating to the level of endogenous dopamine beta-hydroxylase activity in the patient before administering the therapeutic agent. | 10-17-2013 |
20130273023 | DETECTION, ISOLATION AND USES OF RENALASE (MONOAMINE OXIDASE C) - The present invention provides for the identification, isolation and uses of mammalian Monoamine Oxidase C (MAO-C), also known as renalase. | 10-17-2013 |
20130272444 | SPARSE SUPERPOSITION ENCODER AND DECODER FOR COMMUNICATIONS SYSTEM - A computationally feasible encoding and decoding arrangement and method for transmission of data over an additive white Gaussian noise channel with average codeword power constraint employs sparse superposition codes. The code words are linear combinations of subsets of vectors from a given dictionary, with the possible messages indexed by the choice of subset. An adaptive successive decoder is shown to be reliable with error probability exponentially small for all rates below the Shannon capacity. | 10-17-2013 |
20130252832 | KRAS Variant and Tumor Biology - The disclosure provides methods for identifying a subject at risk of developing cancer, predicting the onset of cancer, and predicting a subject's response to chemotherapy/treatment by determining the presence or absence of a SNP in the KRAS oncogene, known as the KRAS variant. | 09-26-2013 |
20130238266 | CONSUMPTION BREAKDOWN MONITORING THROUGH POWER STATE SENSING - Systems and methods are provided for estimating power breakdowns for a set of one or more appliances inside a building by exploiting a small number of power meters and data indicative of binary power states of individual appliances of such set. In one aspect, a breakdown estimation problem is solved within a tree configuration, and utilizing a single power meter and data indicative of binary power states of a plurality of appliances. Based at least in part on such solution, an estimation quality metric is derived. In another aspect, such metric can be exploited in a methodology for optimally placing additional power meters to increase the estimation certainty for individual appliances to a desired or intended level. Estimated power breakdown and energy breakdown—individually or collectively referred to as consumption breakdown—rely on measurements and numerical simulations, and can be evaluated in exemplary electrical network utilizing binary sensors. | 09-12-2013 |
20130223691 | Systems and Methods for Sketching Designs in Context - A method, a system, and a computer program product for graphically representing physical objects in a contextual setting are disclosed. A first data for a predetermined location, at least one distance measurement between at least two location points at the predetermined location, and at least one image of at least one portion of the predetermined location can be received. Based on the receiving and information obtained from at least one publicly available resource, a spatial representation of the predetermined location configured to include at least one existing feature can be generated. Spatial representation of the predetermined location includes a detailed representation of the at least one portion of the predetermined location having the at least one existing feature. | 08-29-2013 |
20130222385 | Systems And Methods For Sketching And Imaging - A method, a system, and a computer program product for generating a three-dimensional representation of a scene within a three-dimensional space are disclosed. A plurality of two-dimensional planes to be positioned within the three-dimensional space are generated. The plurality of two dimensional planes include two-dimensional content that is capable of being modified. The generated two-dimensional planes are positioned within the three-dimensional space. The positioning of the planes is capable of being modified. | 08-29-2013 |
20130217749 | MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION - Provided herein are methods, compounds, and compositions for reducing expression of phosphoenolpyruvate carboxykinase-mitochondrial (PEPCK-M) mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for preventing or decreasing diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of diabetes, obesity, metabolic syndrome, diabetic dyslipidemia, and/or hypertriglyceridemia, or a symptom thereof. | 08-22-2013 |
20130209468 | Use of MIF and MIF Pathway Agonists - The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying a subject at risk for developing a condition in which increased AMPK activity is desirable, and for predicting whether a subject is susceptible to a condition in which increased AMPK activity is desirable. | 08-15-2013 |
20130203112 | Site-Specific Incorporation of Phosphoserine Into Proteins in Escherichia Coli - Nucleic acids encoding mutant elongation factor proteins (EF-Sep), phosphoseryl-tRNA synthetase (SepRS), and phosphoseryl-tRNA (tRNA | 08-08-2013 |
20130190355 | DUAL INHIBITORS OF FARNESYLTRANSFERASE AND GERANYLGERANYLTRANSFERASE I - Many GTPases such as Ras, Ral and Rho require post-translational farnestylation or geranylgeranylation for mediating malignant transformation. Dual farnesyltransferase (FT) (FTI) and geranylgeranyltransferase-I (GGT-1) inhibitors (GGTI) were developed as anticancer agents from based on an ethylenediamine scaffold. On the basis of a 4-fold substituted ethylenediamine scaffold, the inhibitors are structurally simple and readily derivatized, facilitating extensive structure-activity relationship studies. The most potent inhibitor is compound exhibited an in vitro hFTase IC | 07-25-2013 |
20130184594 | Apparatus, Systems and Methods Analyzing Pressure and Volume Waveforms in the Vasculature - Apparatus, systems and methods are provided for analyzing relative compliance in the peripheral vasculature. Such apparatus, systems and methods generally involve generating a plethysmograph (PG) signal, generating one or more pressure waveforms and comparing the pressure waveform(s) relative to the PG signal to determine compliance indexes associated particular regions of the vasculature. A relative compliance ratio may also be determined by comparing arterial and venous relative compliance indexes. Apparatus, systems and methods are also provided for analyzing a PG waveform. Such apparatus, systems and methods generally involve generating a plethysmograph (PG) signal and comparing amplitude modulation of the PG signal relative to baseline modulation of the PG signal to estimate a relationship between left ventricular end diastolic pressure and stroke volume. The estimated relationship may account for a phase offset for the time between when changes in venous return affect left ventricular end diastolic pressure and stroke volume. | 07-18-2013 |
20130172702 | Method of Assessing Blood Volume Using Photoelectric Plethysmography - A method and system for assessing blood volume within a subject includes generating a cardiovascular waveform representing physiological characteristics of a subject and determining blood volume of the subject by analyzing the cardiovascular waveform. The step of analyzing includes generating a first trace of the per heart-beat maximums of the cardiovascular waveform, which is representative of the systolic pressure upon the cardiovascular signal, generating a second trace of the per heart-beat minimums of the cardiovascular waveform, which is representative of the diastolic pressure upon the cardiovascular signal, and comparing the respective first trace and the second trace to generate an estimate of relative blood volume within the subject. In accordance with an alternate method of analyzing harmonic analysis is applied to the cardiovascular waveform, extracting a frequency signal created by ventilation and applying the extracted frequency signal in determining blood volume of the subject. | 07-04-2013 |
20130172682 | Tissue Retractor Assembly - A tissue retractor assembly is provided having a cannula which houses a grasper and an anchor, the grasper extended axially from the cannula, the grasper having legs for gripping tissue and a locking ring for locking the legs, and an anchor having sharpened legs, the grasper being secured and adjusted relative to the anchor by a length of suture. Another tissue retractor assembly is provided having a cannula which houses an anchor, a wire form and a grasper, the wire form a coiled spring which expands radially, and a grasper for pulling tissue through the form. A further retractor assembly is provided having a cannula which houses an anchor and a grasper, the grasper a loop of suture configured to grasp and tighten around tissue. Another tissue retractor assembly is provided having a cannula which houses a first and second graspers, the graspers defined by C-shaped clips. | 07-04-2013 |
20130171157 | NOGO Receptor-Mediated Blockade of Axonal Growth - Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease. | 07-04-2013 |
20130156750 | Compositions and Methods for Using Human YKL-40 to Treat Acute Lung Injury - The invention includes methods of treating oxidant-mediated acute lung injury in a subject by administration of a chitinase-like protein molecule, or an activator thereof. The invention also includes methods of assessing the level of a chitinase-like protein molecule in a subject as a marker of the prognosis of a subject suffering from acute lung injury. | 06-20-2013 |
20130150230 | BULK METALLIC GLASS NANOWIRES FOR USE IN ENERGY CONVERSION AND STORAGE DEVICES - A class of materials has advantageous utility in electrocatalytic applications, e.g., fuel cells. The materials circumvent conventional Pt-based anode poisoning and the agglomeration/dissolution of supported catalysts during long-term operation by exploiting the unique physical and chemical properties of bulk metallic glass to create nanowires for electrocatalytic applications, e.g., fuel cell and battery applications. These amorphous metals can achieve unusual geometries and shapes along multiple length scales. The absence of crystallites, grain boundaries and dislocations in the amorphous structure of bulk metallic glasses results in a homogeneous and isotropic material down to the atomic scale, which displays very high strength, hardness, elastic strain limit and corrosion resistance. The melting temperatures of the disclosed bulk metallic glasses are much lower than the estimated melting temperatures based on interpolation of the alloy constituents making them attractive as highly malleable materials. | 06-13-2013 |
20130143955 | Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use - Disclosed are compositions and methods involving cyclic di-GMP—responsive Riboswitches and cyclic di-GMP-II motifs. | 06-06-2013 |
20130143763 | METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance. | 06-06-2013 |
20130137590 | Assessment of Oocyte Competence - Methods are provided for evaluating an oocyte for fertilization and implantation. For example, methods are provided for determining whether an oocyte expresses, or does not express, one or more of a group of markers identified as differently expressed between chromosomally normal and chromosomally abnormal oocytes. Also provided, for example, are methods for determining whether a cumulus cell expresses, or does not express, one or more of a group of markers identified as differently expressed between cumulus cells associated with chromosomally normal oocytes and cumulus cells associated with chromosomally abnormal oocytes. Methods are provided for the detection of marker expression of differentially expressed genes at the RNA level, as well as at the protein level. | 05-30-2013 |
20130137086 | HPV DNA Methylation Patterns of Diagnostic or Prognostic Significance in Cervical Cancer Screening - Disclosed are methods, compositions, devices, and systems for assessing cancer potential, state, stage, risk of progression, prognosis, etc. of a subject based on determining the methylation state of human papillomavirus (HPV) in a sample from the subject. The cancers assessed generally can be cancer associated with or caused by HPV. For example, cervical cancer, vulvar cancer, penile cancer, anal cancer, and head and neck cancer can be associated with HPV. It has been discovered that certain patterns, profiles, and sets of methylation of HPV genomes are correlated with different cancer potential, state, stage, risk of progression, prognosis, etc. | 05-30-2013 |
20130136751 | Methods, Compositions and Kits Relating to Chitnases and Chitnase-Like Molecules and Inflammation Disease - The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease. | 05-30-2013 |
20130131438 | System and Method for Regulating Brain Activity - The present invention includes systems and methods of using real-time neurofeedback to improve the correspondence between first-person experience and specific brain activation patterns in a manner that minimally affects the experience itself. The present invention provides meditators the ability to enhance their control over their own brain activity, such as posterior cingulate cortex (PCC) activation. The present invention also provides methods for treating a disease or disorder of a subject by measuring the subject's brain activity via fMRI, presenting a representation of the measured brain activity to the subject, and instructing the subject to reduce the represented brain activity by altering their meditative state. The present invention also provides a system and method of using fMRI neurofeedback to directly correlate subjective experience with neural activation. | 05-23-2013 |
20130127982 | EFFICIENTLY DISTRIBUTING VIDEO CONTENT USING A COMBINATION OF A PEER-TO-PEER NETWORK AND A CONTENT DISTRIBUTION NETWORK - A method, system and computer program product for efficiently distributing video content. A peer-to-peer network and a content distribution network are used in combination to distribute video content. A content distribution network relies on servers distributed across the Internet to achieve high quality content delivery at a high cost. A peer-to-peer network distributes content among peers without incurring server side cost but may experience poor performance. The peer-to-peer network and the content distribution network are leveraged in a manner that achieves high content delivery and low cost by allowing the peer-to-peer network to serve as much content as possible while using the content distribution network to bootstrap the content in the peer-to-peer network and using it as a fallback whenever the peer-to-peer network has insufficient bandwidth, insufficient quality or when the missing piece of video content in the video buffer of the client device has an immediate deadline. | 05-23-2013 |
20130127981 | EFFICIENTLY DISTRIBUTING VIDEO CONTENT USING A COMBINATION OF A PEER-TO-PEER NETWORK AND A CONTENT DISTRIBUTION NETWORK - A method, system and computer program product for efficiently distributing video content. A peer-to-peer network and a content distribution network are used in combination to distribute video content. A content distribution network relies on servers distributed across the Internet to achieve high quality content delivery at a high cost. A peer-to-peer network distributes content among peers without incurring server side cost but may experience poor performance. The peer-to-peer network and the content distribution network are leveraged in a manner that achieves high content delivery and low cost by allowing the peer-to-peer network to serve as much content as possible while using the content distribution network to bootstrap the content in the peer-to-peer network and using it as a fallback whenever the peer-to-peer network has insufficient bandwidth, insufficient quality or when the missing piece of video content in the video buffer of the client device has an immediate deadline. | 05-23-2013 |
20130101688 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy. | 04-25-2013 |
20130093768 | Systems and Methods for Creating Texture Exemplars - A system, method and a computer-readable medium for creating texture exemplars from images are provided. The texture exemplars are created by receiving an image containing a plurality of pixels representing a plurality of textures, wherein each texture in the plurality of textures is configured to be selectable by a user, determining a desired texture in the plurality of textures contained within the image and defining a scale of the desired texture, generating a heat mapping of the image, wherein the heat mapping indicates location of the desired texture, generating, based on the heat mapping, a plurality of tiles corresponding to the defined scale of the desired texture, and generating an exemplar of desired texture. | 04-18-2013 |
20130090405 | Polymeric Composites Having Oriented Nanomaterials and Methods of Making the Same - The present invention relates to the development and fabrication of thin-film polymer nanocomposites containing vertically aligned nanomaterials, such as single-walled carbon nanotubes (SWNTs). In certain embodiments, the present invention utilizes liquid crystal mesophases of hexagonally packed cylindrical micelles that orient with their long axes parallel to an applied magnetic field, thereby directing the alignment of the nanomaterials, such as SWNTs, sequestered in the micellar cores. In certain embodiments, the mesophase may be a stable, single-phase material containing monomers that can be polymerized after nanotube alignment to form the nanocomposite polymer. | 04-11-2013 |
20130089862 | Genetic Lesion Associated With Cancer - The invention comprises methods for identifying mutations within the 3′UTR of genes that lead to increased risk or probability of developing cancer. | 04-11-2013 |
20130071397 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTORS AND METHODS OF USE THEREOF - The present invention provides moieties that bind to the most membrane-proximal Ig-like domain of the ectodomain (D7) of vascular endothelial growth factor (VEGF) receptors, wherein the moieties antagonize the activity of the VEGF receptor. | 03-21-2013 |
20130066050 | CHLAMYDOMONAS INTRAFLAGELLAR TRANSPORT 88 (IFT-88) - The invention relates to various intraflagellar transport (IFT) polypeptides and the nucleic acids that encode them. The new IFT particle polypeptides and nucleic acids can be used in a variety of diagnostic, screening, and therapeutic methods. | 03-14-2013 |
20130065778 | MicroRNA Signatures Predicting Responsiveness To Anti-HER2 Therapy - The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab. | 03-14-2013 |
20130042330 | HUMANIZED M-CSF MICE - Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc. | 02-14-2013 |
20130035290 | Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury - The present invention provides compositions and methods for the detection, treatment, and prevention of a kidney injury. The invention relates to the discovery that chitinase 3-like 1/Brp-39/YKL-40 serves as both a biomarker for the degree of kidney injury and a critical mediator of a reparative response in the kidney. | 02-07-2013 |
20130029342 | GLYCINE RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH GLYCINE RIBOSWITCHES - Riboswitches are structural elements in mRNA that change state when bound by a trigger molecule, and are thus able to regulate gene expression. They can be dissected into two separate domains: one that selectively binds the target (aptamer domain) and another that influences genetic control (expression platform domain). Bacterial glycine riboswitches consist of two tandem aptamer domains which cooperatively bind glycine to regulate the expression of downstream genes. These natural switches are targets for antibiotics and other small molecule therapies. Modified versions of these natural riboswitches can be employed as designer genetic switches that are controlled by specific effector compounds. Disclosed are isolated and recombinant riboswitches, and compositions and methods for selecting and identifying compounds that can activate, inactivate, or block a riboswitch. | 01-31-2013 |
20130026387 | SYSTEM AND METHOD FOR TRAPPING AND MEASURING A CHARGED PARTICLE IN A LIQUID - A system and method for trapping a charged particle is disclosed. A time-varying periodic multipole electric potential is generated in a trapping volume. A charged particle under the influence of the multipole electric field is confined to the trapping volume. A three electrode configuration giving rise to a 3D Paul trap and a four planar electrode configuration giving rise to a 2D Paul trap are disclosed. | 01-31-2013 |
20130024957 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 01-24-2013 |
20130012527 | PREQ1 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH PREQ1 RIBOSWITCHES | 01-10-2013 |
20130011656 | Conductivity Based on Selective Etch for GaN Devices and Applications Thereof - This invention relates to methods of generating NP gallium nitride (GaN) across large areas (>1 cm | 01-10-2013 |
20120329720 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. | 12-27-2012 |
20120329665 | SYSTEMS AND METHODS FOR AUTOMATED ANALYSIS OF CELLS AND TISSUES - Systems and methods for rapidly analyzing cell containing samples, for example to identify morphology or to localize and quantitate biomarkers are disclosed. | 12-27-2012 |
20120328599 | INHIBITORS OF RECEPTOR TYROSINE KINASES (RTK) AND METHODS OF USE THEREOF - The present invention provides moieties that bind to the asymmetric contact interface of a receptor tyrosine kinase (RTK), wherein the moieties inhibit ligand induced trans autophosphorylation of the RTK. The present invention also provides methods of treating or preventing an RTK-associated disease and methods for identifying moieties that bind to an asymmetric contact interface of an RTK. | 12-27-2012 |
20120321647 | STRUCTURED RNA MOTIFS AND COMPOUNDS AND METHODS FOR THEIR USE - Disclosed are compositions and methods involing riboswitches and RNA motifs. For example, disclosed are compositions and methods involving glutamine-responsive riboswitches, S-adenosylmethionine-repsonsive riboswitches, S-adenosylhomocysteine-repsonsive riboswitches, glutamine riboswitches, SAM/SAH riboswitches, glnA riboswitches, Downstream-peptide riboswitches, crcB riboswitches, pfl riboswitches, yjdF riboswitches, manA riboswitches, wcaG riboswitches, epsC riboswitches, ykkC-III riboswitches, psaA riboswitches, psbA riboswitches, PhotoRC-I riboswitches, PhotoRC-II riboswitches, and psbNH riboswitches. | 12-20-2012 |
20120315248 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATTENUATED ONCOLYTIC VIRUSES - Compositions including attenuated oncolytic viruses and methods of their use for the treatment of cancer are disclosed. Some attenuated virus exhibit potential as tumor therapies by exhibiting characteristics such as high selectivity, infectivity, cytotoxicity, or replication index for tumor cells, and/or low infectivity, cytotoxicity, or replication index for normal cells. In preferred embodiments, the ratio of replication of virus in normal cells:tumor cells is about 1:100 or greater. Preferred viruses have two or more mechanisms of attenuation including insertion of a transgene such as GFP or an interferon, preferably at position 1 of the viral genome. The compositions can be administered to subjects having tumors, in an effective amount to delay or inhibit the growth of a tumor, reduce the growth or size of the tumor, and/or inhibit or reduce metastasis of the tumor. Methods for manufacturing viruses and methods of testing their oncolytic potential are also disclosed. | 12-13-2012 |
20120310916 | Query Execution Systems and Methods - System, method and computer program product for processing a query are disclosed. Query processing includes partitioning the stored data into a plurality of partitions based on at least one vertex in the plurality of vertexes, storing at least another triple in the plurality of triples on the at least one node, assigning, based on the triple containing the at least one vertex, at least one partition in the plurality of partitions corresponding to the triple to at least one node in the plurality of nodes, and processing, based on the assigning, the query by processing the plurality of partitions. | 12-06-2012 |
20120276220 | Method of Treating Hepatitis - The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient. | 11-01-2012 |
20120271554 | Systems and Methods Utilizing Plethysmographic Data - Disclosed are apparatus, systems and methods utilizing attributes of the cardiac signal to calibrate/normalize components of the plethysmographic (PG) waveform indicating changes in venous and arterial blood volume. In the time-domain, amplitudes of respiratory-induced variations of the DC and AC components of the PG waveform may be calibrated/normalized based on an average amplitude of the PG waveform, e.g., over a respiratory cycle. Similarly, in the frequency domain, respiratory signal strength and side-band signal strength may be advantageously calibrated/normalized based on the strength of the cardiac signal or a harmonic thereof. | 10-25-2012 |
20120269766 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS - The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-H′ function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-H's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein. | 10-25-2012 |
20120252096 | MUTANT PROTEINASE WITH REDUCED SELF-CLEAVAGE ACTIVITY AND METHOD OF PURIFICATION - The present invention provides a mutant 27 kDa NIa proteinase having reduced self-cleavage activity relative to the self-cleavage activity of its wild-type proteinase. The mutant has the same substrate cleavage activity as the wild-type proteinase but is more stable than the wild-type proteinase. The present invention also provides a method of obtaining large quantities of active 27 kDa NIa proteinase for use as a tool for purification of other proteins. | 10-04-2012 |
20120228222 | Forward Osmosis Separation Processes - Separation processes using forward osmosis are disclosed generally involving the extraction of a solvent from a first solution to concentrate a solute therein by using a second concentrated solution to draw the solvent from the first solution across a semi-permeable membrane. One or both of the solute and solvent may be a desired product. By manipulating the equilibrium of the soluble and insoluble species of solute within the second solution, a saturated second solution can be used to generate osmotic pressure on the first solution. The various species of solute within the second solution can be recovered and recycled through the process to affect the changes in equilibrium and eliminate waste products. Enhanced efficiency may result from using low grade waste heat from industrial or commercial sources. | 09-13-2012 |
20120225931 | COMPOSITIONS AND METHODS FOR INHIBITING INFLAMMATION FROM AND REJECTION OF BIOMATERIALS AND OTHER METHODS - The present invention relates, inter alia, to methods and compositions for regulating the host response to biomaterials, including inhibiting inflammation from and rejection of biomaterials using salicylate compounds and/or TLR7/TLR9 antagonists as described herein. | 09-06-2012 |
20120225832 | Amphiphilic Compositions and Methods for Preparing and Using Same - The invention relates to amphiphilic C-glycoside derivatives, to methods of using them and to processes for synthesizing them. Specifically, the invention relates to novel cyclic and linear enone-glycolipids and cyclic ketone-glycolipids. | 09-06-2012 |
20120219958 | MicroRNA Signatures Differentiating Uterine and Ovarian Papillary Serous Tumors - The invention provides a papillary serous miRNA signature and methods for determining the identity, origin, and stage, of concurrent endometrial and ovarian papillary serous tumors. Exemplary origins of concurrent endometrial and ovarian tumors include, but are not limited to, the uterus, ovary, fallopian tubes, and peritoneum. | 08-30-2012 |
20120219567 | Methods Relating to Peripheral Administration of Nogo Receptor Polypeptides - This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides. | 08-30-2012 |
20120171246 | IMMUNIZATION TO REDUCE NEUROTOXICITY DURING TREATMENT WITH CYTOLYTIC VIRUSES - Methods for protecting the brain and other tissues from virus-associated toxicity are provided. Patients are treated with a first immunizing virus prior to administration of a second, therapeutic cytolytic virus. The immunizing virus is preferably administered peripherally, and initiates an adaptive immune response that is sufficient to reduce or prevent the cytovirulence and inflammation caused by the therapeutic virus. The immunizing virus is administered one or more times, preferably at least twice, before administration of the therapeutic virus. The therapeutic virus can be the same virus as the immunizing virus, or a mutant or variant thereof. Preferably the therapeutic virus is an attenuated virus with reduced virulence compared to the immunizing virus. | 07-05-2012 |
20120165877 | Method For Stabilizing A Spine - Spine stabilization devices, systems and methods are provided in which a single resilient member or spring is disposed on an elongate element that spans two attachment members attached to different spinal vertebrae. The elongate element passes through at least one of the two attachment members, permitting relative motion therebetween, and terminates in a stop or abutment. A second resilient member is disposed on the elongate element on an opposite side of the sliding attachment member, e.g., in an overhanging orientation. The two resilient members are capable of applying mutually opposing urging forces, and a compressive preload can be applied to one or both of the resilient members. | 06-28-2012 |
20120157324 | METHYLATION BIOMARKERS AND METHODS OF USE - Disclosed are methods and compositions of assessing one or more statuses of a subject. Also disclosed are methods and compositions of identifying status biomarkers associated with a status of a subject. Also disclosed are sets of one or more status biomarkers. Also disclosed are methods and compositions of producing status biomarker capture probes. | 06-21-2012 |
20120150030 | Instruments, Methods and Systems for Harvesting and Implanting Cartilage Material - The present disclosure provides instruments and systems for accessing and removing hyaline cartilage from desired donor sites. The present disclosure also provides instruments/systems for implantation of hyaline cartilage grafts, e.g., to fill osteochondral defects. The apparatus/systems may be used in connection with mapping techniques and systems. Thus, in exemplary embodiments of the present disclosure, a clinician may be guided in his use of the disclosed apparatus/systems by articular joint surface mapping data in locating/identifying harvest sites for “best fit” grafts, i.e., grafts that exhibit desired geometric and/or surface attributes for use in particular implantation site(s). Alternatively, the disclosed instruments/systems may be employed to access anatomical sites independent of such mapping techniques/systems. | 06-14-2012 |
20120150002 | Systems and Methods Utilizing Plethysmographic Data for Distinguishing Arterial and Venous Saturations - Apparatus, systems and methods are provided for using the PG waveform to determine peripheral venous and arterial saturations. Generally, saturations are determined by isolating an indicator of venous or arterial blood volume in each of a plurality of PG waveforms and using the isolated indicators to determine saturation in the corresponding region of the vasculature. Indicators may include respiratory induced variations of AC and/or DC components of the PG waveforms, peaks of the PG waveforms, troughs of the PG waveforms, venous pulsations of the PG waveforms, etc. Indicators may further be isolated in either the time or frequency domain. The isolated indicators may advantageously be normalized, e.g., based on a baseline of the PG waveform or a derivative thereof. | 06-14-2012 |
20120149651 | Caveolin peptides and their use as therapeutics - The present invention relates generally to compositions and methods useful for treating various conditions and afflictions, such as inflammation and cancer. More specifically, the present invention relates to compositions and methods of treatment which utilize peptides comprising at least one caveolin scaffolding domain. Even more specifically, the present invention relates to compositions of fusion peptides comprising the antennapedia homeodomain fused to a caveolin scaffolding domain and to methods of using these peptides to treat various conditions and afflictions. | 06-14-2012 |
20120142042 | Selective Delivery Of Molecules Into Cells Or Marking Of Cells In Diseased Tissue Regions Using Environmentally Sensitive Transmembrane Peptide - A polypeptide with a predominantly hydrophobic sequence long enough to span a membrane lipid bilayer as a transmembrane helix (TM) and comprising one or more dissociable groups inserts across a membrane spontaneously in a pH-dependant fashion placing one terminus inside cell. The polypeptide conjugated with various functional moieties delivers and accumulates them at cell membrane with low extracellular pH. The functional moiety conjugated with polypeptide terminus placed inside cell are translocated through the cell membrane in cytosol. The peptide and its variants or non-peptide analogs can be used to deliver therapeutic, prophylactic, diagnostic, imaging, gene regulation, cell regulation, or immunologic agents to or inside of cells in vitro or in vivo in tissue at low extracellular pH. | 06-07-2012 |
20120135000 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. | 05-31-2012 |
20120115782 | COMPOSITIONS AND METHODS FOR TREATING OR INHIBITING LIVER INJURY - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates inter alia to methods of inhibiting or reducing the likelihood of liver injury secondary to hepatitis, cirrhosis and a number of other disease states and conditions and further may be used to reduce the likelihood of a patient at risk or treating a patient for inter alia hepatitis, cirrhosis, non-alcoholic fatty liver diseases (NAFLD), non-alcoholic steatohepatitis (NASH), cirrhosis and other disease states and conditions as otherwise described. Pharmaceutical compositions are also described. | 05-10-2012 |
20120115140 | Molecular Diagnosis of Fragile X Syndrome Associated with FMR1 Gene - The present invention includes a rapid, selective, and accurate method of diagnosing a human subject with a triplet repeat genetic disorder of the FMR1 gene that leads to fragile X syndrome. The present invention also includes a rapid, selective, and accurate method of diagnosing a human subject at risk for developing a triplet repeat genetic disorder of the FMR1 gene that leads to fragile X syndrome, or at risk of passing such a disorder on to their progeny. | 05-10-2012 |
20120101028 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. | 04-26-2012 |
20120100537 | Method of Prenatal Molecular Diagnosis of Down Syndrome and Other Trisomic Disorders - The present invention encompasses a method of diagnosing chromosomal trisomy in a human subject. In one embodiment, the method comprises pyrosequencing at least one single nucleotide polymorphism on a chromosome being assessed for trisomy, where the SNP comprises two alleles. | 04-26-2012 |
20120091062 | Osmotic Desalination Process - An energy efficient desalination process that does not produce waste products involves the extraction of water from a first solution, such as seawater, by using a second concentrated solution to draw the water from the first solution across a semi-permeable membrane. By manipulating the equilibrium of the soluble and insoluble species of solute within the second solution in favor of the soluble species of the solute, a saturated second solution can be used to generate osmotic pressure on the first solution. Also, by adjusting the equilibrium in favor of the less soluble species after the water has been drawn from the first solution, a portion of the solute can easily be precipitated out. Heating the second solution decomposes the solute into its constituent gases. The constituent gases and precipitated solute may be recycled through the process to affect the changes in equilibrium and eliminate waste products. Additionally, by using the waste steam from industrial sources and a heat pump to effectively distribute heat through the present method, the present method exhibits greater energy efficiency than prior art methods. | 04-19-2012 |
20120088216 | Systems and Methods for Monitoring, Evaluation, and Treatment - A computer-implemented method, a computer program product, and a system are provided. A plurality of multi-level cognitive exercises are provided to an individual. Each of the multi-level cognitive exercises includes at least one task to perform. The individual is requested to respond to a cognitive exercise in the plurality of cognitive exercises by performing the at least one task contained in the cognitive exercise. A response provided by the individual to the cognitive exercise is monitored. Based on the monitoring, a determination is made whether the individual performed the at least one task at a predetermined performance level, wherein the performance level is defined by the at least one task contained in the cognitive exercise. Based on the determining, the individual is requested to perform at least another task. At least one activity for the individual to perform is generated. The at least one activity is based on responses to the multi-level cognitive exercises by the individual. | 04-12-2012 |
20120082686 | Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. | 04-05-2012 |
20120071421 | THERAPY WITH CLOSTRIDIUM PERFRINGENS ENTEROTOXIN TO TREAT OVARIAN AND UTERINE CANCER - The invention discloses high levels of receptors for | 03-22-2012 |
20120064050 | Tissue Engineering of Lung - The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery. | 03-15-2012 |
20120058125 | METHODS RELATING TO PERIPHERAL ADMINISTRATION OF NOGO RECEPTOR POLYPEPTIDES - This invention relates to methods of treating diseases involving accumulation of Aβ plaques, including Alzheimer's Disease by the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of increasing the plasma to brain ratio of Aβ peptide and enhancing Aβ peptide clearance via peripheral administration of soluble Nogo receptor polypeptides. This invention also provides methods of improving memory function or inhibiting memory loss via the peripheral administration of soluble Nogo receptor polypeptides. The invention also provides methods of decreasing the size and number of Aβ plaques in a mammal via peripheral administration of soluble Nogo receptor polypeptides. | 03-08-2012 |
20120040974 | MIF MODULATORS - The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression. | 02-16-2012 |
20120040371 | DIAGNOSIS OF PREECLAMPSIA - The present invention provides methods and compositions related to the detection and/or monitoring of the levels of angiogenic factors, specifically VEGF, PlGF and sFlt-1, in urine samples obtained from pregnant women and the effects of such levels on the risk of developing complications of pregnancy, including hypertensive disorders such as preeclampsia, in the first, second, and/or third trimester of pregnancy. The present invention also provides kits for identifying and screening patients at risk of developing a complication of pregnancy, such as preeclampsia. | 02-16-2012 |
20120039865 | IDENTIFICATION OF SORTILIN AS A NEURONAL RECEPTOR FOR THE FRONTOTEMPORAL DEMENTIA PROTEIN, PROGRANULIN - The present invention is related to methods for identifying compounds that modulate the interaction between progranulin and sortilin. The present invention is also related to methods for modulating the interaction between progranulin and sortilin, the activity of progranulin or sortilin, or the activity of progranulin and sortilin. The present invention also includes methods of treating or preventing a disease, disorder, or condition by modulating the interaction between progranulin and sortilin, the activity of progranulin or sortilin, or the activity of progranulin and sortilin. | 02-16-2012 |
20120035184 | METHODS FOR INDUCING TUMOR REGRESSION, INHIBITING TUMOR GROWTH, AND INDUCING APOPTOSIS IN BREAST TUMORS WITH GERANYLGERANYLTRANSFERASE I INHIBITORS - Methods of inducing tumor regression, inhibiting tumor growth, and inducing apoptosis with selective peptidomimetic inhibitors of geranylgeranyltransferase I (GGTase I), are provided. In one aspect, GGTI-2418 and its methylester GGTI-2417, increase levels of the cyclin-dependent kinase (Cdk) inhibitor p27 | 02-09-2012 |
20120021442 | MARKERS FOR DETECTION OF COMPLICATIONS RESULTING FROM IN UTERO ENCOUNTERS - Described herein are biomarkers, such as protein biomarkers, which are diagnostic of and predictive for complications that result from an in utero encounter, such as an infection by the fetus, that can lead to premature birth (PTB). The biomarkers can be used to identify fetuses and newborns at risk for complications of PTB, such as (Early Onset Neonatal Sepsis) EONS, intra-ventricular hemorrhage (IVH) and other poor outcomes. | 01-26-2012 |
20120009282 | USE OF THE COMBINATION OF PHY906 AND A TYROSINE KINASE INHIBITOR AS A CANCER TREATMENT REGIMEN - This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of cancer by administering the herbal composition PHY906 in combination with one or more chemotherapeutic compounds to a mammal undergoing such chemotherapy. | 01-12-2012 |
20120004261 | MIF MODULATORS - The invention provides novel heterocyclic compounds, pharmaceutical compositions and methods of treatment that modulate levels of MIF expression and treat disorders associated with high or low levels of MIF expression. | 01-05-2012 |
20110313459 | Dynamic Spine Stabilizer - A dynamic spine stabilizer moves under the control of spinal motion providing increased mechanical support within a central zone corresponding substantially to the neutral zone of the injured spine. The dynamic spine stabilizer includes a support assembly and a resistance assembly associated with the support assembly. The resistance assembly generates greater increase in mechanical force during movement within the central zone and lesser increase in mechanical force during movement beyond the central zone. A method for using the stabilizer is also disclosed. | 12-22-2011 |
20110311538 | INHIBITORS OF RECEPTOR TYROSINE KINASES AND METHODS OF USE THEREOF - The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase. | 12-22-2011 |
20110302583 | SYSTEMS AND METHODS FOR PROCESSING DATA - A system, method, and computer program product for processing data are disclosed. The system includes a data processing framework configured to receive a data processing task for processing, a plurality of database systems coupled to the data processing framework, wherein the database systems are configured to perform a data processing task, and a storage component in communication with the data processing framework and the plurality database systems, configured to store information about each partition of the data processing task being processed by each database system and the data processing framework. The data processing task is configured to be partitioned into a plurality of partitions and each database system is configured to process a partition of the data processing task assigned for processing to that database system. Each database system is configured to perform processing of its assigned partition of the data processing task in parallel with another database system processing another partition of the data processing task assigned to the another database system. The data processing framework is configured to perform at least one partition of the data processing task. | 12-08-2011 |
20110302226 | DATA LOADING SYSTEMS AND METHODS - System, method, and computer program product for processing data are disclosed. The system is configured to perform transfer of data from a file system to a database system. Such transfer is accomplished through receiving a request for loading data into a database system, wherein the data includes a plurality of attributes, determining at least one attribute of the data for loading into the database system, and loading the at least one attribute of the data into the database system while continuing to process remaining attributes of the data. | 12-08-2011 |
20110302151 | Query Execution Systems and Methods - System, method, and computer program product for processing data are disclosed. The method includes receiving a query for processing of data, wherein the data is stored in a table in a plurality of tables, wherein the table is stored on at least one node within the database system, determining an attribute of the table and another table in the plurality of tables, partitioning one of the table and the another table in the plurality of tables using the determined attribute into a plurality of partitions, and performing a join of at least two partitions of the table and the another table using the determined attribute. The join is performed on a single node in the database system. | 12-08-2011 |
20110300152 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS - Compositions and methods are provided for modulating cell-cell fusion by using agents that modulate expression, activity, or function of intermediate-conductance calcium-activated potassium (SK4) channel. In some embodiments, the compositions and methods of the invention provide for inhibition of multi-nucleated osteoclastogenesis and cell-cell fusion, especially cell fusion involving macrophages. In such embodiments, the compositions can comprise inhibitory nucleic acids, monoclonal antibodies or small molecule inhibitors of the SK4 channels and find use in preventing and/or treating various diseases or disorders including bone loss, autoimmune and inflammatory diseases or disorders, implant and transplant rejection, and cancer metastasis. In other embodiments, the compositions and methods of the invention provide for activation of cell-cell fusion. Also provided are methods to screen for SK4 channel modulators (inhibitors or activators) that modulate cell-cell fusion, particularly macrophage cell fusion. | 12-08-2011 |
20110293750 | ACTIVATED WNT-BETA-CATENIN SIGNALING IN MELANOMA - The present invention is directed to a method of determining the prospects for survival of a melanoma patient. This method involves providing a biological sample from a patient diagnosed with melanoma, determining the level of an indicator of Wnt/β-catenin activation in the sample, comparing the level of the indicator of Wnt/β-catenin activation in the sample against a standard level of the indicator of Wnt/β-catenin activation correlated to survival of melanoma, and determining a patient's prospects for survival of melanoma based on the comparison. The present invention also relates to a method of improving survival of melanoma patients, decreasing metastases in melanoma patients, decreasing proliferation of cancer cells in melanoma patients, decreasing melanoma recurrence in melanoma patients, and/or decreasing tumor size in melanoma patients. This involves selecting melanoma patients and subsequently determining and monitoring therapy based on their level of Wnt/β-catenin activation. The selected melanoma patients are treated with a dose of an activator or synergizer of Wnt/β-catenin based on the patient's level of Wnt/β-catenin, under conditions effective, respectively, to improve survival of the selected melanoma patients, to decrease metas-tases in the selected melanoma patients, to decrease proliferation of cancer cells in the selected melanoma patients, to decrease melanoma recurrence in the selected melanoma patients, and/or to decrease tumor size in the selected melanoma patients. | 12-01-2011 |
20110281358 | System For Seeding Cells Onto Three Dimensional Scaffolds - Systems are provided for convenient and sterile isolation, collection, and seeding of cells onto a scaffold or tissue graft. The systems may be closed. Methods for use of the disclosed systems for isolation, collection and seeding of cells and generation of tissue engineered vascular grafts are also provided. The systems may be supplied in kits for efficient and expeditious use. | 11-17-2011 |
20110280863 | METHODS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF PREECLAMPSIA - Methods, kits and compounds are provided that relate to the diagnosis, treatment, and/or prevention of preeclampsia. | 11-17-2011 |
20110262406 | COMPOSITIONS AND METHODS FOR TARGETED INACTIVATION OF HIV CELL SURFACE RECEPTORS - Compositions for targeted mutagenesis of cell surface receptors for HIV and methods of their use are provided herein. The compositions include triplex-forming molecules that displace the polypyrimidine strand of target duplex and form a triple-stranded structure and hybrid duplex in a sequence specific manner with the polypurine strand of the target duplex. The triplex-forming molecules include a mixed-sequence “tail” which increases the stringency of binding to the target duplex, improves the frequency of modification at the target site, and reduces the requirement for a polypurine:polypyrimidine stretch. Methods for using the triplex-forming molecules in combination with one or more donor oligonucleotides for targeted modification of sites within or adjacent to genes that encodes cell surface receptors for human immunodeficiency virus (HIV) are also disclosed. Methods for ex vivo and in vivo prophylaxis and therapy of HIV infection using the disclosed compositions are also provided. | 10-27-2011 |
20110206773 | SUSTAINED DELIVERY OF DRUGS FROM BIODEGRADABLE POLYMERIC MICROPARTICLES - Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing or one or more diseases or disorders of the eye, and methods of making and using thereof, are described. The microsphere compositions release an effective amount of the one or more active agents for a period greater than 14 days in vivo, preferably greater than 60 days in vivo, more preferably up to 73 days in vivo, more preferably greater than 90 days in vivo, even more preferably over 100 days in vivo, and most preferably greater than 107 days in vivo. In a preferred embodiment, the microparticle compositions contain one or more active agents such as AG1478 to induce nerve regeneration, specifically regeneration of the optic nerve useful for managing elevated intraocular pressure (TOP) in the eye. | 08-25-2011 |
20110203994 | Forward Osmosis Separation Processes - Separation processes using engineered osmosis are disclosed generally involving the extraction of solvent from a first solution to concentrate solute by using a second concentrated solution to draw the solvent from the first solution across a semi-permeable membrane. One or both of the solute and solvent may be a desired product. Enhanced efficiency may result from using low grade waste heat from industrial or commercial sources. | 08-25-2011 |
20110201563 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS - The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule. | 08-18-2011 |
20110200982 | GENETICALLY MODIFIED MICE AND ENGRAFTMENT - A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mIl2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/Il2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., | 08-18-2011 |
20110196428 | Method for stabilizing a spine - Spine stabilization devices, systems and methods are provided in which a single resilient member or spring is disposed on an elongate element that spans two attachment members attached to different spinal vertebrae. The elongate element passes through at least one of the two attachment members, permitting relative motion therebetween, and terminates in a stop or abutment. A second resilient member is disposed on the elongate element on an opposite side of the sliding attachment member, e.g., in an overhanging orientation. The two resilient members are capable of applying mutually opposing urging forces, and a compressive preload can be applied to one or both of the resilient members. | 08-11-2011 |
20110196018 | Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases - External Guide Sequence (EGS) are described that target proteins required for generation and modification of the immunoglobulin and T-cell repertoire that are useful for treatment or prevention of inflammatory or related diseases. Formulations suitable for administration of an EGS for treatment of inflammatory or related disease are described. The formulations may be administered via inhalation, injection, or orally. The formulations may be in the form of an ointment, lotion, cream, gel, drop, suppository, spray, liquid, powder, granule, solution, suspension, capsule, or tablet. Methods of treating inflammatory or related diseases by administering an effective amount of an EGS in a pharmaceutically acceptable carrier are also described. In preferred embodiments, the disease is asthma, allergic rhinitis, food allergies, atopic skin disease such as eczema, IL-4 and/or IL-13 dependent malignancies, IL-4 and/or IL-13 dependent autoimmune diseases, atopic diseases, the flu, and diseases caused by IL-4 dependent replication of viruses. | 08-11-2011 |
20110160119 | ANTI-INFLAMMATORY COMPOUNDS AND USES THEREOF - The present invention provides anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compounds and methods of inhibiting NF-κB-dependent target gene expression in a cell. | 06-30-2011 |
20110144137 | METHOD FOR PREVENTING OR ALLEVIATING THE NOXIOUS EFFECTS RESULTING FROM TOXICANT EXPOSURE - The present invention provides a method of using agents which can modulate TRPA1 function as counteragents to inhibit the physical effects of chemical irritants/toxicants when given prior to exposure or to lessen the physical effects when administered post exposure, and more specifically, to a method for counteracting the acute physical noxious effects of toxicants, including but not limited to, tear gases, chlorine, hydrogen peroxide, ammonia, phosgene, chloropicrin, isocyanates and mustard gas. Administering the counteragents counteracts pain, inflammation, lachrymation, blepharospasm, respiratory irritation and depression, airway mucus secretion, airway obstruction and injury, cough and incapacitation and cutaneous chemical injuries. Another embodiment provides a method of preventing or treating a disease or condition in a mammal, which disease or condition includes hypersensitivity to chemical stimuli, particularly in regards to inflammatory airway conditions, such as asthma, rhinitis, etc., by administering to the mammal a therapeutically effective amount of a compound that inhibits TRPA1 function, wherein the compound reduces the hypersensitivity and mediates the response to such chemical stimuli in the mammal. The invention also includes a kit containing the compound that inhibits the TRPA1 function as a counteracting agent for administration prior to or post exposure to prevent or limit the effects of the exposure. | 06-16-2011 |
20110136743 | Survivin, a protein that inhibits cellular apoptosis, and its modulation - The present invention provides the amino acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agents that block Survivin mediated inhibition of cellular apoptosis, methods of using agents that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity. | 06-09-2011 |
20110125003 | Systems, Devices and Methods For Cartilage and Bone Grafting - Disclosed are systems, methods, devices and products to identify suitable donor sites for harvesting bone-cartilage grafts and to implant such bone-cartilage grafts. In some embodiments, a method includes providing a computer having access to a donor database, the donor database comprising information on each of a plurality of donor joint sites of the body, receiving first data relating to a defect of a joint of a patient, the defect comprising an area of bone, a portion of which includes at least one of, for example, missing and/or damaged cartilage, and identifying, based on the first data, at least one donor site from the donor database of joints for harvesting a graft of bone and cartilage to repair the defect. | 05-26-2011 |
20110117114 | Neovascular-Targeted Immunoconjugates - Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. | 05-19-2011 |
20110117094 | Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury - Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent. | 05-19-2011 |
20110104108 | METHODS OF TREATING CANCER AND OTHER CONDITIONS OR DISEASE STATES USING LFMAU AND LDT - The present invention relates to the use of the compound according to formula (I), below for the treatment of tumors, cancer and hyperproliferative diseases, among other conditions or disease states: Where X is H or F; R | 05-05-2011 |
20110082385 | METHOD FOR IMPLANTING INTRAOCULAR PRESSURE SENSOR - Methods of implanting an intraocular pressure sensor and systems tbr sensing intraocular pressure are disclosed. An intraocular pressure sensor, including, a top surface, may be placed through the sclera of an eye of a patient. The intraocular pressure sensor may be caused to be inserted into the sclera until the top surface of the intraocular pressure sensor is substantially flush with the exterior wall of the sclera. An implantation wand may be used to assist in the insertion process. The wand may be disengaged from the tntraocuiar pressure sensor after it has been implanted. | 04-07-2011 |
20110081421 | METHODS OF REGULATING RENALASE (MONOAMINE OXIDASE C) - The present invention provides methods of using Monoamine Oxidase C (MAO-C), also known as renalase, as a therapeutic protein in its active and inactive forms. Administering inactive renalase protein to individuals with lower renalase levels can be used to provide them with an adequate pool of the protein that can be activated by the body as needed. Active renalase protein can be administered to individuals needing an immediate reduction of catecholamine levels. An inhibitor of renalase may be used to enhance adrenergic action. | 04-07-2011 |